Marshall Edwards (MSHL +25%) pops after saying it's initiating phase I clinical trials of its...

|By:, SA News Editor

Marshall Edwards (MSHL +25%) pops after saying it's initiating phase I clinical trials of its lead drug candidate ME-143 for patients with refractory solid tumors.